<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25210968</article-id>
      <article-id pub-id-type="pmc">4201176</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37132014000400013</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Use of volume-targeted non-invasive bilevel positive airway pressure
ventilation in a patient with amyotrophic lateral sclerosis<xref ref-type="fn" rid="fn01">*</xref>,<xref ref-type="fn" rid="fn02">**</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Diaz-Abad</surname>
            <given-names>Montserrat</given-names>
          </name>
          <role>Physician</role>
          <aff>Sleep Disorders Center, University of Maryland; and Assistant Professor of
Medicine. University of Maryland School of Medicine, Baltimore, MD,
<country>USA</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brown</surname>
            <given-names>John Edward</given-names>
          </name>
          <role>Physician</role>
          <aff>Sleep Disorders Center, University of Maryland; and Assistant Professor of
Medicine. University of Maryland School of Medicine, Baltimore, MD,
<country>USA</country></aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><bold>Correspondence to:</bold> Montserrat Diaz-Abad. Sleep Disorders Center,
Division of Pulmonary and Critical Care Medicine, University of Maryland School of
Medicine. 685 West Baltimore Street, MSTF 800, Baltimore, Maryland, 21201, USA. Tel.
1 410 706-4771. Fax: 1 410 706-0345. E-mail: <email>mdiaz@kunhardt.net</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jul-Aug</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2014</year>
      </pub-date>
      <volume>40</volume>
      <issue>4</issue>
      <fpage>443</fpage>
      <lpage>447</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>6</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>8</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in
which most patients die of respiratory failure. Although volume-targeted non-invasive
bilevel positive airway pressure (BPAP) ventilation has been studied in patients with
chronic respiratory failure of various etiologies, its use in ALS has not been
reported. We present the case of a 66-year-old woman with ALS and respiratory failure
treated with volume-targeted BPAP ventilation for 15 weeks. Weekly data downloads
showed that disease progression was associated with increased respiratory muscle
weakness, decreased spontaneous breathing, and increased use of non-invasive positive
pressure ventilation, whereas tidal volume and minute ventilation remained relatively
constant.</p>
      </abstract>
      <kwd-group>
        <kwd>Amyotrophic lateral sclerosis</kwd>
        <kwd>Respiratory insufficiency</kwd>
        <kwd>Hypoventilation</kwd>
        <kwd>Intermittent positive-pressure ventilation</kwd>
        <kwd>Sleep</kwd>
      </kwd-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="2"/>
        <ref-count count="12"/>
        <page-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease. Most ALS
patients die of respiratory failure due to progressive respiratory muscle weakness, with
a median survival of less than 2 years after diagnosis.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup> Non-invasive positive pressure ventilation (NPPV) prolongs and improves the
quality of life of patients with ALS.<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> The use of volume-targeted, non-invasive bilevel positive airway pressure
(BPAP) ventilation, in spontaneous-timed (ST) mode with adjustment of inspiratory
pressure to provide an estimated target tidal volume (V<sub>T</sub>), has been studied
in patients with chronic respiratory failure of various etiologies. <sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>-</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup> However, we are unaware of any reports of its use in a patient with ALS. </p>
      <p>We report the case of a patient with ALS with rapidly progressive disease and
hypercapnic respiratory failure who was treated at home with volume-targeted BPAP ST
mode ventilation. Weekly monitoring of downloaded ventilator data was accompanied by
routine clinical follow-up.</p>
    </sec>
    <sec>
      <title>Case report</title>
      <p>A 66-year-old woman without a significant past medical history and with a body mass
index of 23.4 kg/m<sup>2</sup> presented with mild bulbar symptoms followed by right
foot drop. At 11 months after symptom onset, she was diagnosed with ALS. At that time,
FVC was 2.22 L (79% of predicted) and MIP was &#x2212;28 cmH<sub>2</sub>O (40% of predicted).
Her ALS Functional Rating Scale (ALSFRS) score was 34 (out of 40) with a bulbar
component score of 10 (out of 12), denoting mild impairment. Her Pittsburgh Sleep
Quality Index (PSQI) score was 8 (out of 21), which is consistent with poor sleep
quality, whereas her Epworth Sleepiness Scale (ESS) score was 4 (out of 24), indicating
no evidence of excessive daytime sleepiness. </p>
      <p>At 4 months of follow-up, marked disease progression was evident, with worsening bulbar
symptoms and fatigue, as were new conversational dyspnea, orthopnea, and nonrestorative
sleep. Her pulmonary function and functional status had declined-FVC, 1.58 L (57% of
predicted); MIP, &#x2212;25 cmH<sub>2</sub>O (36% of predicted)-and her ALSFRS score was 28
with a bulbar component score of 8. Sleep scores were relatively unchanged (PSQI, 7;
ESS, 4). An arterial blood gas could not be obtained after two attempts. Gastrostomy and
NPPV were recommended. The patient requested further confirmatory testing prior to these
interventions, and overnight in-laboratory polysomnography was scheduled for the
following week.</p>
      <p>Polysomnography revealed sleep hypoventilation. Three weeks later, volume-targeted BPAP
ST ventilation titration (Average Volume-Assured Pressure Support; Philips-Respironics,
Murrayville, PA, USA) was performed using a full face mask, per patient preference
(<xref ref-type="table" rid="t01">Table 1</xref>). The patient could not tolerate the
target V<sub>T</sub> (8 mL/kg). Therefore, the final settings were V<sub>T</sub> at 320
mL (6 mL/kg), inspiratory positive airway pressure at 8-15 cmH<sub>2</sub>O, expiratory
positive airway pressure at 6 cmH<sub>2</sub>O (increased for flow limitation), and
inspiratory time at 1.5 s, with a backup rate of 12 breaths/min. One week later, the
patient returned to the clinic with continued worsening of bulbar symptoms and weakness,
using a walker, and reporting dyspnea on minimal exertion. Her FVC was 1.05 L (38% of
predicted), with an MIP of &#x2212;19 cmH<sub>2</sub>O (27% of predicted) and a
PaCO<sub>2</sub> of 53 mmHg. Her ALSFRS score was 26, with a bulbar component score
of 6, her PSQI score was 17, and her ESS score was 7. Nocturnal NPPV was started with
polysomnography settings and a backup rate of 14 breaths/min.</p>
      <p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title>Sleep study data in a patient with amyotrophic lateral sclerosis.</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 50%"><thead><tr><th rowspan="2" colspan="1">Parameter</th><th colspan="2" rowspan="1">Type of study<sup>a</sup>
</th></tr><tr><th rowspan="1" colspan="1">PSG</th><th rowspan="1" colspan="1">AVAPS</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> Total sleep time, min</td><td rowspan="1" colspan="1"> 250</td><td rowspan="1" colspan="1"> 116</td></tr><tr><td rowspan="1" colspan="1"> Sleep efficiency, %</td><td rowspan="1" colspan="1"> 55</td><td rowspan="1" colspan="1"> 32</td></tr><tr><td rowspan="1" colspan="1"> Sleep latency, min</td><td rowspan="1" colspan="1"> 58</td><td rowspan="1" colspan="1"> 113</td></tr><tr><td rowspan="1" colspan="1"> Total wake time, min (%)</td><td rowspan="1" colspan="1"> 203 (45)</td><td rowspan="1" colspan="1"> 242 (65)</td></tr><tr><td rowspan="1" colspan="1"> Stage 1, min (%)</td><td rowspan="1" colspan="1"> 5 (1)</td><td rowspan="1" colspan="1"> 15 (4)</td></tr><tr><td rowspan="1" colspan="1"> Stage 2, min (%)</td><td rowspan="1" colspan="1"> 175 (39)</td><td rowspan="1" colspan="1"> 99 (27)</td></tr><tr><td rowspan="1" colspan="1"> Stage 3, min (%)</td><td rowspan="1" colspan="1"> 71 (16)</td><td rowspan="1" colspan="1"> 15 (4)</td></tr><tr><td rowspan="1" colspan="1"> REM, min (%)</td><td rowspan="1" colspan="1"> 0 (0)</td><td rowspan="1" colspan="1"> 0 (0)</td></tr><tr><td rowspan="1" colspan="1"> Wake after sleep onset, min</td><td rowspan="1" colspan="1"> 143</td><td rowspan="1" colspan="1"> 31</td></tr><tr><td rowspan="1" colspan="1"> Arousal index, events/h</td><td rowspan="1" colspan="1"> 18</td><td rowspan="1" colspan="1"> 6</td></tr><tr><td rowspan="1" colspan="1"> Spontaneous arousals, n</td><td rowspan="1" colspan="1"> 67</td><td rowspan="1" colspan="1"> 11</td></tr><tr><td rowspan="1" colspan="1"> Periodic limb movement <break/> index,
events/h</td><td rowspan="1" colspan="1"> 1</td><td rowspan="1" colspan="1"> 0</td></tr><tr><td rowspan="1" colspan="1"> Apnea hypopnea index, events/h</td><td rowspan="1" colspan="1"> 0</td><td rowspan="1" colspan="1"> 0</td></tr><tr><td rowspan="1" colspan="1"> Mean nocturnal SpO<sub>2</sub>, %</td><td rowspan="1" colspan="1"> 95</td><td rowspan="1" colspan="1"> 97</td></tr><tr><td rowspan="1" colspan="1"> Minimum SpO<sub>2</sub>, %</td><td rowspan="1" colspan="1"> 93</td><td rowspan="1" colspan="1"> 94</td></tr><tr><td rowspan="1" colspan="1"> Baseline ETCO<sub>2</sub>, mmHg</td><td rowspan="1" colspan="1"> 46</td><td rowspan="1" colspan="1"> 47-54</td></tr><tr><td rowspan="1" colspan="1"> Maximum ETCO<sub>2</sub>, mmHg</td><td rowspan="1" colspan="1"> 57</td><td rowspan="1" colspan="1"> 57</td></tr><tr><td rowspan="1" colspan="1"> ETCO<sub>2</sub> &gt; 50, min</td><td rowspan="1" colspan="1"> 227</td><td rowspan="1" colspan="1"> 121</td></tr><tr><td rowspan="1" colspan="1"> Baseline RR, breaths/min</td><td rowspan="1" colspan="1"> -</td><td rowspan="1" colspan="1"> 24</td></tr><tr><td rowspan="1" colspan="1"> Final ETCO<sub>2</sub>, mmHg</td><td rowspan="1" colspan="1"> -</td><td rowspan="1" colspan="1"> 35-45</td></tr><tr><td rowspan="1" colspan="1"> Final RR, breaths/min</td><td rowspan="1" colspan="1"> -</td><td rowspan="1" colspan="1"> 12-14</td></tr></tbody></table><table-wrap-foot><fn id="t01TFN01"><label>PSG</label><p>: polysomnography</p></fn><fn id="t01TFN02"><p><bold>AVAPS:</bold> : average volume-assured pressure support</p></fn><fn id="t01TFN03"><label>REM</label><p>: rapid-eye-movement sleep</p></fn><fn id="t01TFN04"><p><bold>ETCO2:</bold> : end-tidal CO2</p></fn><fn id="t01TFN05"><label>a</label><p>The patient performed both studies recumbent at approximately 45&#xB0;.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>A gastrostomy tube was inserted under radiological guidance, and the patient started
home hospice, with no plans to return to the clinic. Seven weeks after starting NPPV,
she was contacted to adjust settings based on symptoms and downloaded data (<xref ref-type="table" rid="t02">Table 2</xref> and <xref ref-type="fig" rid="f01">Figure
1</xref>), and the patient decided to come to the clinic for a short visit to discuss
her worsening dyspnea. She had mild dyspnea at rest and required a wheelchair for
mobility. Nocturnal NPPV, which was used every night, helped ease breathing, allowing
her to sleep better and longer. She had recently developed a mask leak due to weight
loss. At that time, FVC was 1.01 L (36% of predicted), MIP was &#x2212;15 cmH<sub>2</sub>O (21%
of predicted) and PaCO<sub>2</sub> was 55 mmHg. Settings were adjusted to V<sub>T</sub>
at 370 mL (7 mL/kg), inspiratory positive airway pressure at 10-17 cmH<sub>2</sub>O, and
inspiratory time at 1.2 s, with a backup rate of 18 breaths/min. Intermittent daytime
NPPV use and a new mask fitting were recommended. Contact with the patient (via
telephone and e-mail) was maintained, and the changes were well tolerated. At 6 weeks
after her last visit, she was again contacted to adjust settings but declined to make
further changes. Shortly thereafter, she died of progressive respiratory failure. </p>
      <p>
<table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><title>Weekly ventilator data downloads for an amyotrophic lateral sclerosis
patient on bilevel positive airway pressure ventilation.</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 50%"><thead><tr><th rowspan="2" colspan="1">Variable</th><th colspan="15" rowspan="1">Week</th></tr><tr><th rowspan="1" colspan="1">1</th><th rowspan="1" colspan="1">2</th><th rowspan="1" colspan="1">3</th><th rowspan="1" colspan="1">4</th><th rowspan="1" colspan="1">5</th><th rowspan="1" colspan="1">6</th><th rowspan="1" colspan="1">7</th><th rowspan="1" colspan="1">8</th><th rowspan="1" colspan="1">9</th><th rowspan="1" colspan="1">10<sup>a</sup>
</th><th rowspan="1" colspan="1">11</th><th rowspan="1" colspan="1">12</th><th rowspan="1" colspan="1">13</th><th rowspan="1" colspan="1">14</th><th rowspan="1" colspan="1">15</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> V<sub>E</sub>, L/min</td><td rowspan="1" colspan="1"> 4.3</td><td rowspan="1" colspan="1"> 4.5</td><td rowspan="1" colspan="1"> 4.4</td><td rowspan="1" colspan="1"> 4.4</td><td rowspan="1" colspan="1"> 4.3</td><td rowspan="1" colspan="1"> 4.5</td><td rowspan="1" colspan="1"> 5.8</td><td rowspan="1" colspan="1"> 5.4</td><td rowspan="1" colspan="1"> 5.5</td><td rowspan="1" colspan="1"> 6.5</td><td rowspan="1" colspan="1"> 7.1</td><td rowspan="1" colspan="1"> 6.4</td><td rowspan="1" colspan="1"> 5.9</td><td rowspan="1" colspan="1"> 6.3</td><td rowspan="1" colspan="1"> 6.5</td></tr><tr><td rowspan="1" colspan="1"> V<sub>T</sub>, mL</td><td rowspan="1" colspan="1"> 271</td><td rowspan="1" colspan="1"> 267</td><td rowspan="1" colspan="1"> 266</td><td rowspan="1" colspan="1"> 259</td><td rowspan="1" colspan="1"> 265</td><td rowspan="1" colspan="1"> 259</td><td rowspan="1" colspan="1"> 295</td><td rowspan="1" colspan="1"> 273</td><td rowspan="1" colspan="1"> 252</td><td rowspan="1" colspan="1"> 310</td><td rowspan="1" colspan="1"> 354</td><td rowspan="1" colspan="1"> 346</td><td rowspan="1" colspan="1"> 336</td><td rowspan="1" colspan="1"> 336</td><td rowspan="1" colspan="1"> 338</td></tr><tr><td rowspan="1" colspan="1"> Trigger, %</td><td rowspan="1" colspan="1"> 77</td><td rowspan="1" colspan="1"> 82</td><td rowspan="1" colspan="1"> 77</td><td rowspan="1" colspan="1"> 78</td><td rowspan="1" colspan="1"> 76</td><td rowspan="1" colspan="1"> 80</td><td rowspan="1" colspan="1"> 90</td><td rowspan="1" colspan="1"> 87</td><td rowspan="1" colspan="1"> 78</td><td rowspan="1" colspan="1"> 63</td><td rowspan="1" colspan="1"> 55</td><td rowspan="1" colspan="1"> 47</td><td rowspan="1" colspan="1"> 43</td><td rowspan="1" colspan="1"> 46</td><td rowspan="1" colspan="1"> 50</td></tr><tr><td rowspan="1" colspan="1"> Daily use, h</td><td rowspan="1" colspan="1"> 5.0</td><td rowspan="1" colspan="1"> 3.9</td><td rowspan="1" colspan="1"> 6.1</td><td rowspan="1" colspan="1"> 5.7</td><td rowspan="1" colspan="1"> 5.4</td><td rowspan="1" colspan="1"> 5.3</td><td rowspan="1" colspan="1"> 5.6</td><td rowspan="1" colspan="1"> 6.0</td><td rowspan="1" colspan="1"> 10.1</td><td rowspan="1" colspan="1"> 12.9</td><td rowspan="1" colspan="1"> 11.8</td><td rowspan="1" colspan="1"> 12.4</td><td rowspan="1" colspan="1"> 10.3</td><td rowspan="1" colspan="1"> 13.7</td><td rowspan="1" colspan="1"> 17.6</td></tr><tr><td rowspan="1" colspan="1"> Use &#x2265; 4 h/day, %</td><td rowspan="1" colspan="1"> 71</td><td rowspan="1" colspan="1"> 43</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 86</td><td rowspan="1" colspan="1"> 86</td><td rowspan="1" colspan="1"> 86</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 86</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 43</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 100</td></tr><tr><td rowspan="1" colspan="1"> RR, breaths/min</td><td rowspan="1" colspan="1"> 19</td><td rowspan="1" colspan="1"> 19</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 19</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 22</td><td rowspan="1" colspan="1"> 23</td><td rowspan="1" colspan="1"> 25</td><td rowspan="1" colspan="1"> 24</td><td rowspan="1" colspan="1"> 22</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 21</td><td rowspan="1" colspan="1"> 22</td></tr><tr><td rowspan="1" colspan="1"> AHI, events/h</td><td rowspan="1" colspan="1"> 15.2</td><td rowspan="1" colspan="1"> 19.4</td><td rowspan="1" colspan="1"> 25.8</td><td rowspan="1" colspan="1"> 21.6</td><td rowspan="1" colspan="1"> 19.1</td><td rowspan="1" colspan="1"> 23.2</td><td rowspan="1" colspan="1"> 5.2</td><td rowspan="1" colspan="1"> 13.4</td><td rowspan="1" colspan="1"> 22.3</td><td rowspan="1" colspan="1"> 26.8</td><td rowspan="1" colspan="1"> 7.7</td><td rowspan="1" colspan="1"> 15.1</td><td rowspan="1" colspan="1"> 11.4</td><td rowspan="1" colspan="1"> 5.5</td><td rowspan="1" colspan="1"> 12.7</td></tr><tr><td rowspan="1" colspan="1"> Leak, L/min</td><td rowspan="1" colspan="1"> 40</td><td rowspan="1" colspan="1"> 40</td><td rowspan="1" colspan="1"> 41</td><td rowspan="1" colspan="1"> 38</td><td rowspan="1" colspan="1"> 42</td><td rowspan="1" colspan="1"> 38</td><td rowspan="1" colspan="1"> 36</td><td rowspan="1" colspan="1"> 39</td><td rowspan="1" colspan="1"> 41</td><td rowspan="1" colspan="1"> 38</td><td rowspan="1" colspan="1"> 38</td><td rowspan="1" colspan="1"> 36</td><td rowspan="1" colspan="1"> 36</td><td rowspan="1" colspan="1"> 35</td><td rowspan="1" colspan="1"> 36</td></tr><tr><td rowspan="1" colspan="1"> IPAP, cmH<sub>2</sub>O</td><td rowspan="1" colspan="1"> 11.9</td><td rowspan="1" colspan="1"> 11.9</td><td rowspan="1" colspan="1"> 12.9</td><td rowspan="1" colspan="1"> 12.8</td><td rowspan="1" colspan="1"> 12.5</td><td rowspan="1" colspan="1"> 12.6</td><td rowspan="1" colspan="1"> 10.9</td><td rowspan="1" colspan="1"> 11.8</td><td rowspan="1" colspan="1"> 13.5</td><td rowspan="1" colspan="1"> 15.0</td><td rowspan="1" colspan="1"> 13.8</td><td rowspan="1" colspan="1"> 13.5</td><td rowspan="1" colspan="1"> 14.2</td><td rowspan="1" colspan="1"> 14.0</td><td rowspan="1" colspan="1"> 14.5</td></tr></tbody></table><table-wrap-foot><fn id="t02TFN01"><label>VE</label><p>: minute ventilation</p></fn><fn id="t02TFN02"><label>VT</label><p>: tidal volume</p></fn><fn id="t02TFN03"><p><bold>Trigger:</bold> : patient-triggered (spontaneous) breaths</p></fn><fn id="t02TFN04"><p><bold>Daily use:</bold> : device use per 24-h period</p></fn><fn id="t02TFN05"><label>Use </label><p>= 4 h/day: days on which the device was used for = 4 h/day</p></fn><fn id="t02TFN06"><label>AHI</label><p>: apnea-hypopnea index</p></fn><fn id="t02TFN07"><label>Leak</label><p>: total mask leak</p></fn><fn id="t02TFN08"><label>IPAP</label><p>: inspiratory positive airway pressure.</p></fn><fn id="t02TFN09"><label>a</label><p>Ventilator support increased between weeks 8 and 9; week 10 reflects this
increase for the first complete week</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Ventilator data for a 15-week period in an amyotrophic lateral sclerosis
patient on bilevel positive airway pressure ventilation. Note the increased
duration of daily use of ventilation with decreased ability to trigger breaths
spontaneously (i.e., increased reliance on timed ventilator-delivered breaths)
over time. As can be seen, minute ventilation remained relatively constant.
*Ventilator support increased between weeks 8 and 9; week 10 reflects this
increase for the first complete week.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-04-00443-gf01"/></fig>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>We have presented the case of a patient with ALS treated for chronic respiratory failure
with volume-targeted BPAP ST mode ventilation for 15 weeks, in whom the use of weekly
monitoring of ventilator data in addition to routine care provided useful information
for management of respiratory failure. Disease progression was associated with worsening
respiratory muscle weakness, a decrease in spontaneous breathing, and increased use of
NPPV, although V<sub>T</sub> and minute ventilation (V<sub>E</sub>) remained relatively
constant. To our knowledge, the use of this mode of NPPV has not been reported in ALS. </p>
      <p>Among patients with ALS, the progression of the disease is relatively rapid but
varies.<sup>(</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> Therefore, serial NPPV pressure adjustments may be required in order to
compensate for declining respiratory muscle strength and increasing hypercapnia.
<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>)</sup> An NPPV mode with an inspiratory pressure range to maintain a target
V<sub>T</sub>, rather than a fixed pressure, might reduce the frequency of required
adjustments over time in some patients. This feature might also be of benefit in the
short term, such as during sleep, when patients with diaphragmatic weakness are
vulnerable to worsening hypoventilation, especially during rapid-eye-movement sleep.
Ambogrio et al. showed that, in comparison with traditional BPAP ST mode ventilation,
volume-targeted BPAP ST mode ventilation was better able to maintain V<sub>E</sub> (by
maintaining V<sub>T</sub>) during sleep in patients with obesity hypoventilation
syndrome.<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup>
</p>
      <p>The built-in software of NPPV devices is proprietary, and, in the absence of independent
validation, the data provided on many parameters should be considered as indicators of
trends without any guarantee as to linearity of the estimations provided.<sup>(</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>)</sup> Despite this limitation, the available data can provide valuable
information for patient management. Studies involving remote monitoring of NPPV
compliance data in patients with ALS using traditional BPAP ventilation have shown that
such monitoring reduces health care utilization and hospital admissions, potentially
reducing overall health care costs, in comparison with routine care.<sup>(</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup> This monitoring modality could be particularly useful in patients with
rapidly progressive or advanced ALS, who, like our patient, might be homebound. The
ability to request and verify changes to the settings remotely (without a home visit) is
an additional advantage.</p>
      <p>Volume-targeted BPAP ST mode ventilation is a relatively new alternative to traditional
NPPV for patients with respiratory failure, and we have reported its use for the first
time in a patient with ALS. Additional studies are needed in order to compare the
various NPPV modes, in terms of their effect on survival, quality of life, sleep
quality, adherence, adequacy of ventilation, and health care utilization, in ALS
patients.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial support: None.</p>
      </fn>
      <fn id="fn01" fn-type="supported-by">
        <label>*</label>
        <p> Study carried out in the Division of Pulmonary and Critical Care Medicine,
University of Maryland School of Medicine, Baltimore, MD, USA</p>
      </fn>
      <fn id="fn02" fn-type="other">
        <label>**</label>
        <p> A vers&#xE3;o completa em portugu&#xEA;s deste artigo est&#xE1; dispon&#xED;vel em
www.jornaldepneumologia.com.br</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Louwerse</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Visser</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Bossuyt</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Weverling</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Amyotrophic lateral sclerosis: mortality risk during the
course of the disease and prognostic factors. The Netherlands ALS
Consortium</article-title>
          <source>J Neurol Sci</source>
          <year>1997</year>
          <volume>152</volume>
          <issue>1</issue>
          <fpage>S10</fpage>
          <lpage>S17</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0022-510X(97)00238-4">http://dx.doi.org/10.1016/S0022-510X(97)00238-4</ext-link>
          <pub-id pub-id-type="pmid">9419048</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bourke</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Tomlinson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Bullock</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Effects of non-invasive ventilation on survival and
quality of life in patients with amyotrophic lateral sclerosis: a randomised
controlled trial</article-title>
          <source>Lancet Neurol</source>
          <year>2006</year>
          <volume>5</volume>
          <issue>2</issue>
          <fpage>140</fpage>
          <lpage>147</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(05)70326-4">http://dx.doi.org/10.1016/S1474-4422(05)70326-4</ext-link>
          <pub-id pub-id-type="pmid">16426990</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Storre</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Seuthe</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fiechter</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Milioglou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dreher</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sorichter</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Average volume-assured pressure support in obesity
hypoventilation: A randomized crossover trial</article-title>
          <source>Chest</source>
          <year>2006</year>
          <volume>130</volume>
          <issue>3</issue>
          <fpage>815</fpage>
          <lpage>821</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.130.3.815">http://dx.doi.org/10.1378/chest.130.3.815</ext-link>
          <pub-id pub-id-type="pmid">16963680</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ambrogio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lowman</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Malo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Prasad</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Parthasarathy</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Sleep and non-invasive ventilation in patients with
chronic respiratory insufficiency</article-title>
          <source>Intensive Care Med</source>
          <year>2009</year>
          <volume>35</volume>
          <issue>2</issue>
          <fpage>306</fpage>
          <lpage>313</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00134-008-1276-4">http://dx.doi.org/10.1007/s00134-008-1276-4</ext-link>
          <pub-id pub-id-type="pmid">18795255</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janssens</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Metzger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sforza</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Impact of volume targeting on efficacy of bi-level
non-invasive ventilation and sleep in obesity-hypoventilation</article-title>
          <source>Respir Med</source>
          <year>2009</year>
          <volume>103</volume>
          <issue>2</issue>
          <fpage>165</fpage>
          <lpage>172</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2008.03.013">http://dx.doi.org/10.1016/j.rmed.2008.03.013</ext-link>
          <pub-id pub-id-type="pmid">18579368</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crisafulli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Manni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kidonias</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Trianni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Clini</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Subjective sleep quality during average volume assured
pressure support (AVAPS) ventilation in patients with hypercapnic COPD: a
physiological pilot study</article-title>
          <source>Lung</source>
          <year>2009</year>
          <volume>187</volume>
          <issue>5</issue>
          <fpage>299</fpage>
          <lpage>305</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00408-009-9167-1">http://dx.doi.org/10.1007/s00408-009-9167-1</ext-link>
          <pub-id pub-id-type="pmid">19672655</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vagiakis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Koutsourelakis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Perraki</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Roussos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mastora</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zakynthinos</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Average volume-assured pressure support in a 16-year-old
girl with congenital central hypoventilation syndrome</article-title>
          <source>J Clin Sleep Med</source>
          <year>2010</year>
          <volume>6</volume>
          <issue>6</issue>
          <fpage>609</fpage>
          <lpage>612</lpage>
          <pub-id pub-id-type="pmid">21206552</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murphy</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hind</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Simonds</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Hopkinson</surname>
              <given-names>NS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Volume targeted versus pressure support non-invasive
ventilation in patients with super obesity and chronic respiratory failure: a
randomised controlled trial</article-title>
          <source>Thorax</source>
          <year>2012</year>
          <volume>67</volume>
          <issue>8</issue>
          <fpage>727</fpage>
          <lpage>734</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/thoraxjnl-2011-201081">http://dx.doi.org/10.1136/thoraxjnl-2011-201081</ext-link>
          <pub-id pub-id-type="pmid">22382596</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Radunovic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mitsumoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Leigh</surname>
              <given-names>PN</given-names>
            </name>
          </person-group>
          <article-title>Clinical care of patients with amyotrophic lateral
sclerosis</article-title>
          <source>Lancet Neurol</source>
          <year>2007</year>
          <volume>6</volume>
          <issue>10</issue>
          <fpage>913</fpage>
          <lpage>925</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(07)70244-2">http://dx.doi.org/10.1016/S1474-4422(07)70244-2</ext-link>
          <pub-id pub-id-type="pmid">17884681</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gruis</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Lisabeth</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Zebarah</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Chervin</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>Longitudinal assessment of noninvasive positive pressure
ventilation adjustments in ALS patients</article-title>
          <source>J Neurol Sci</source>
          <year>2006</year>
          <volume>247</volume>
          <issue>1</issue>
          <fpage>59</fpage>
          <lpage>63</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jns.2006.03.007">http://dx.doi.org/10.1016/j.jns.2006.03.007</ext-link>
          <pub-id pub-id-type="pmid">16631799</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janssens</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Borel</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>P&#xE9;pin</surname>
              <given-names>JL</given-names>
            </name>
            <collab>SomnoNIV Group</collab>
          </person-group>
          <article-title>Nocturnal monitoring of home non-invasive ventilation:
the contribution of simple tools such as pulse oximetry, capnography, built-in
ventilator software and autonomic markers of sleep fragmentation</article-title>
          <source>Thorax</source>
          <year>2011</year>
          <volume>66</volume>
          <issue>5</issue>
          <fpage>438</fpage>
          <lpage>445</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/thx.2010.139782">http://dx.doi.org/10.1136/thx.2010.139782</ext-link>
          <pub-id pub-id-type="pmid">20971980</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pinto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Pinto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>de Carvalho</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Home telemonitoring of non-invasive ventilation
decreases healthcare utilisation in a prospective controlled trial of patients
with amyotrophic lateral sclerosis</article-title>
          <source>J Neurol Neurosurg Psychiatry</source>
          <year>2010</year>
          <volume>81</volume>
          <issue>11</issue>
          <fpage>1238</fpage>
          <lpage>1242</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jnnp.2010.206680">http://dx.doi.org/10.1136/jnnp.2010.206680</ext-link>
          <pub-id pub-id-type="pmid">20826878</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Utiliza&#xE7;&#xE3;o de ventila&#xE7;&#xE3;o n&#xE3;o invasiva com dois n&#xED;veis de press&#xE3;o positiva
nas vias a&#xE9;reas e volume alvo em paciente com esclerose lateral amiotr&#xF3;fica<xref ref-type="fn" rid="fn03">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Diaz-Abad</surname>
            <given-names>Montserrat</given-names>
          </name>
          <role>M&#xE9;dica</role>
          <aff>Centro de Dist&#xFA;rbios do Sono, Universidade de Maryland; e Professora Assistente
de Medicina. Faculdade de Medicina da Universidade de Maryland, Baltimore (MD)
<country>EUA</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brown</surname>
            <given-names>John Edward</given-names>
          </name>
          <role>M&#xE9;dico</role>
          <aff>Centro de Dist&#xFA;rbios do Sono, Universidade de Maryland; e Professor Assistente
de Medicina. Faculdade de Medicina da Universidade de Maryland, Baltimore (MD)
<country>EUA</country></aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="c02"><bold>Endere&#xE7;o para correspond&#xEA;ncia:</bold> Montserrat Diaz-Abad. Sleep Disorders
Center, Division of Pulmonary and Critical Care Medicine, University of Maryland
School of Medicine. 685 West Baltimore Street, MSTF 800, Baltimore, Maryland, 21201,
USA. Tel. 1 410 706-4771. Fax: 1 410 706-0345. E-mail:
<email>mdiaz@kunhardt.net</email></corresp>
      </author-notes>
      <abstract>
        <p>A esclerose lateral amiotr&#xF3;fica (ELA) &#xE9; uma doen&#xE7;a neurodegenerativa progressiva. A
maioria dos pacientes com ELA falece por insufici&#xEA;ncia respirat&#xF3;ria. Embora a
ventila&#xE7;&#xE3;o n&#xE3;o invasiva com dois n&#xED;veis de press&#xE3;o positiva nas vias a&#xE9;reas e volume
alvo tenha sido estudada em pacientes com insufici&#xEA;ncia respirat&#xF3;ria cr&#xF4;nica de
diferentes etiologias, sua utiliza&#xE7;&#xE3;o em ELA n&#xE3;o foi relatada. Apresentamos o caso de
uma mulher de 66 anos com ELA e insufici&#xEA;ncia respirat&#xF3;ria tratada com ventila&#xE7;&#xE3;o com
dois n&#xED;veis de press&#xE3;o positiva e volume alvo por 15 semanas. Os dados obtidos
semanalmente mostraram que a progress&#xE3;o da doen&#xE7;a estava associada com aumento da
fraqueza muscular respirat&#xF3;ria, redu&#xE7;&#xE3;o da respira&#xE7;&#xE3;o espont&#xE2;nea e maior uso de
ventila&#xE7;&#xE3;o n&#xE3;o invasiva com press&#xE3;o positiva, enquanto o volume corrente e a
ventila&#xE7;&#xE3;o minuto permaneceram relativamente constantes.</p>
      </abstract>
      <kwd-group>
        <kwd>Esclerose amiotr&#xF3;fica lateral</kwd>
        <kwd>Insufici&#xEA;ncia respirat&#xF3;ria</kwd>
        <kwd>Hipoventila&#xE7;&#xE3;o</kwd>
        <kwd>Ventila&#xE7;&#xE3;o com press&#xE3;o positiva intermitente</kwd>
        <kwd>Sono</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>Introdu&#xE7;&#xE3;o</title>
        <p>A esclerose lateral amiotr&#xF3;fica (ELA) &#xE9; uma doen&#xE7;a neurodegenerativa progressiva. A
maioria dos pacientes com ELA morre de insufici&#xEA;ncia respirat&#xF3;ria em virtude de
fraqueza muscular respirat&#xF3;ria progressiva; a mediana de sobrevida ap&#xF3;s o diagn&#xF3;stico
&#xE9; de menos de 2 anos.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup> A ventila&#xE7;&#xE3;o n&#xE3;o invasiva com press&#xE3;o positiva (VNIPP) prolonga e
melhora a qualidade de vida dos pacientes com ELA.<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup> J&#xE1; se estudou o uso de ventila&#xE7;&#xE3;o n&#xE3;o invasiva com dois n&#xED;veis de
press&#xE3;o positiva nas vias a&#xE9;reas (ventila&#xE7;&#xE3;o BPAP, do ingl&#xEA;s <italic>bilevel positive
airway pressure</italic>) e volume controlado, no modo espont&#xE2;neo-cronometrado
(E-C), com ajuste da press&#xE3;o inspirat&#xF3;ria para fornecer um volume corrente (VC) alvo
estimado, em pacientes com insufici&#xEA;ncia respirat&#xF3;ria cr&#xF4;nica de diferentes
etiologias.<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>-</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup> No entanto, n&#xE3;o estamos cientes de nenhum relato de uso em pacientes com
ELA. </p>
        <p>Relatamos o caso de uma paciente com ELA de progress&#xE3;o r&#xE1;pida e insufici&#xEA;ncia
respirat&#xF3;ria hiperc&#xE1;pnica tratada em casa com ventila&#xE7;&#xE3;o BPAP com volume controlado
no modo E-C. Al&#xE9;m do acompanhamento cl&#xED;nico de rotina, foram monitorados os dados do
ventilador, baixados semanalmente. </p>
      </sec>
      <sec>
        <title>Relato de caso</title>
        <p>Uma mulher de 66 anos de idade, sem hist&#xF3;ria m&#xE9;dica significativa e com &#xED;ndice de
massa corporal de 23,4 kg/m<sup>2</sup>, apresentou sintomas bulbares leves e, em
seguida, "p&#xE9; ca&#xED;do" &#xE0; direita. Onze meses ap&#xF3;s o in&#xED;cio dos sintomas, recebeu
diagn&#xF3;stico de ELA. Na &#xE9;poca, a CVF era de 2,22 L (79% do previsto) e a PIm&#xE1;x era de
&#x2212;28 cmH<sub>2</sub>O (40% do previsto). Obteve 34 pontos (de 40 poss&#xED;veis) na Escala
de Avalia&#xE7;&#xE3;o Funcional da ELA (EAFELA), com 10 pontos (de 12 poss&#xED;veis) no componente
bulbar, o que denota comprometimento leve. Obteve 8 pontos (de 21 poss&#xED;veis) no
&#xCD;ndice de Qualidade do Sono de Pittsburgh (IQSP), o que denota m&#xE1; qualidade do sono,
e 4 (de 24 poss&#xED;veis) na Escala de Sonol&#xEA;ncia de Epworth (ESE), isto &#xE9;, n&#xE3;o havia
evid&#xEA;ncia de sonol&#xEA;ncia diurna excessiva. </p>
        <p>Aos 4 meses de acompanhamento, era evidente a acentuada progress&#xE3;o da doen&#xE7;a, com
agravamento dos sintomas bulbares e fadiga, assim como o eram os novos sintoma de
dispneia durante a conversa&#xE7;&#xE3;o, ortopneia e sono n&#xE3;o reparador. Sua fun&#xE7;&#xE3;o pulmonar e
seu estado funcional haviam piorado - CVF: 1,58 L (57% do previsto); PIm&#xE1;x: &#x2212;25
cmH<sub>2</sub>O (36% do previsto) - e a paciente obteve 28 pontos na EAFELA, com
8 pontos no componente bulbar. A pontua&#xE7;&#xE3;o no IQSP e na ESE permaneceu relativamente
inalterada (IQSP = 7 e ESE = 4). Foram feitas duas tentativas de gasometria arterial,
ambas sem sucesso. Recomendamos gastrostomia e VNIPP. A paciente solicitou mais
testes de confirma&#xE7;&#xE3;o antes dessas interven&#xE7;&#xF5;es; foi ent&#xE3;o marcada para a semana
seguinte uma polissonografia de noite inteira em laborat&#xF3;rio. </p>
        <p>A polissonografia revelou hipoventila&#xE7;&#xE3;o durante o sono. Tr&#xEA;s semanas depois, foi
realizada a titula&#xE7;&#xE3;o da ventila&#xE7;&#xE3;o BPAP em modo E-C com volume controlado
(<italic>Average Volume-Assured Pressure Support</italic>; Philips Respironics,
Murrayville, PA, EUA) por meio de uma m&#xE1;scara facial inteira, por escolha da paciente
(<xref ref-type="table" rid="t03">Tabela 1</xref>). A paciente n&#xE3;o tolerou o VC
alvo (8 mL/kg). Portanto, a configura&#xE7;&#xE3;o final foi a seguinte: VC = 320 mL (6 mL/kg);
press&#xE3;o positiva inspirat&#xF3;ria nas vias a&#xE9;reas = 8-15 cmH<sub>2</sub>O; press&#xE3;o
positiva expirat&#xF3;ria nas vias a&#xE9;reas = 6 cmH<sub>2</sub>O (aumentada para limita&#xE7;&#xE3;o
do fluxo) e tempo inspirat&#xF3;rio = 1,5 s, com frequ&#xEA;ncia de <italic>backup</italic> de
12 ciclos/min. Uma semana depois, a paciente retornou &#xE0; cl&#xED;nica; apresentava
agravamento cont&#xED;nuo dos sintomas bulbares e fraqueza, usava um andador e relatava
dispneia aos m&#xED;nimos esfor&#xE7;os. Sua CVF era de 1,05 L (38% do previsto), com PIm&#xE1;x de
&#x2212;19 cmH<sub>2</sub>O (27% do previsto) e PaCO<sub>2</sub> de 53 mmHg. Obteve 26
pontos na EAFELA (com 6 pontos no componente bulbar), 17 no IQSP e 7 na ESE.
Iniciou-se VNIPP noturna com configura&#xE7;&#xE3;o de polissonografia e frequ&#xEA;ncia de
<italic>backup</italic> de 14 ciclos/min. </p>
        <p>
<table-wrap id="t03" orientation="portrait" position="float"><label>Tabela 1</label><caption><title>Dados do estudo do sono em paciente com esclerose lateral
amiotr&#xF3;fica.</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 50%"><thead><tr><th rowspan="2" colspan="1">Par&#xE2;metro</th><th colspan="2" rowspan="1">Tipo de estudo<sup>a</sup>
</th></tr><tr><th rowspan="1" colspan="1">PSG</th><th rowspan="1" colspan="1">AVAPS</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> Tempo total de sono, min</td><td rowspan="1" colspan="1"> 250</td><td rowspan="1" colspan="1"> 116</td></tr><tr><td rowspan="1" colspan="1"> Efici&#xEA;ncia do sono, %</td><td rowspan="1" colspan="1"> 55</td><td rowspan="1" colspan="1"> 32</td></tr><tr><td rowspan="1" colspan="1"> Lat&#xEA;ncia do sono, min</td><td rowspan="1" colspan="1"> 58</td><td rowspan="1" colspan="1"> 113</td></tr><tr><td rowspan="1" colspan="1"> Tempo total acordada, min (%)</td><td rowspan="1" colspan="1"> 203 (45)</td><td rowspan="1" colspan="1"> 242 (65)</td></tr><tr><td rowspan="1" colspan="1"> Est&#xE1;gio 1, min (%)</td><td rowspan="1" colspan="1"> 5 (1)</td><td rowspan="1" colspan="1"> 15 (4)</td></tr><tr><td rowspan="1" colspan="1"> Est&#xE1;gio 2, min (%)</td><td rowspan="1" colspan="1"> 175 (39)</td><td rowspan="1" colspan="1"> 99 (27)</td></tr><tr><td rowspan="1" colspan="1"> Est&#xE1;gio 3, min (%)</td><td rowspan="1" colspan="1"> 71 (16)</td><td rowspan="1" colspan="1"> 15 (4)</td></tr><tr><td rowspan="1" colspan="1"> Sono REM, min (%)</td><td rowspan="1" colspan="1"> 0 (0)</td><td rowspan="1" colspan="1"> 0 (0)</td></tr><tr><td rowspan="1" colspan="1"> Tempo acordada ap&#xF3;s o in&#xED;cio do sono,
min</td><td rowspan="1" colspan="1"> 143</td><td rowspan="1" colspan="1"> 31</td></tr><tr><td rowspan="1" colspan="1"> &#xCD;ndice de microdespertares, eventos/h</td><td rowspan="1" colspan="1"> 18</td><td rowspan="1" colspan="1"> 6</td></tr><tr><td rowspan="1" colspan="1"> Microdespertares espont&#xE2;neos, n</td><td rowspan="1" colspan="1"> 67</td><td rowspan="1" colspan="1"> 11</td></tr><tr><td rowspan="1" colspan="1"> &#xCD;ndice de movimentos peri&#xF3;dicos dos membros,
eventos/h</td><td rowspan="1" colspan="1"> 1</td><td rowspan="1" colspan="1"> 0</td></tr><tr><td rowspan="1" colspan="1"> &#xCD;ndice de apneia-hipopneia, eventos/h</td><td rowspan="1" colspan="1"> 0</td><td rowspan="1" colspan="1"> 0</td></tr><tr><td rowspan="1" colspan="1"> M&#xE9;dia de SpO<sub>2</sub> noturna, %</td><td rowspan="1" colspan="1"> 95</td><td rowspan="1" colspan="1"> 97</td></tr><tr><td rowspan="1" colspan="1"> SpO<sub>2</sub> m&#xED;nima, %</td><td rowspan="1" colspan="1"> 93</td><td rowspan="1" colspan="1"> 94</td></tr><tr><td rowspan="1" colspan="1"> ETCO<sub>2</sub> basal, mmHg</td><td rowspan="1" colspan="1"> 46</td><td rowspan="1" colspan="1"> 47-54</td></tr><tr><td rowspan="1" colspan="1"> ETCO<sub>2</sub> m&#xE1;ximo, mmHg</td><td rowspan="1" colspan="1"> 57</td><td rowspan="1" colspan="1"> 57</td></tr><tr><td rowspan="1" colspan="1"> ETCO<sub>2</sub> &gt; 50, min</td><td rowspan="1" colspan="1"> 227</td><td rowspan="1" colspan="1"> 121</td></tr><tr><td rowspan="1" colspan="1"> FR basal, ciclos/min</td><td rowspan="1" colspan="1"> -</td><td rowspan="1" colspan="1"> 24</td></tr><tr><td rowspan="1" colspan="1"> ETCO<sub>2</sub> final, mmHg</td><td rowspan="1" colspan="1"> -</td><td rowspan="1" colspan="1"> 35-45</td></tr><tr><td rowspan="1" colspan="1"> FR final, ciclos/min</td><td rowspan="1" colspan="1"> -</td><td rowspan="1" colspan="1"> 12-14</td></tr></tbody></table><table-wrap-foot><fn id="t03TFN01"><label>PSG</label><p>: polissonografia</p></fn><fn id="t03TFN02"><p><bold>AVAPS:</bold> : average volume-assured pressure support (ventila&#xE7;&#xE3;o com m&#xE9;dia de
press&#xE3;o de suporte e volume garantido)</p></fn><fn id="t03TFN03"><label>REM</label><p>: rapid eye movement</p></fn><fn id="t03TFN04"><p><bold>ETCO2:</bold> : di&#xF3;xido de carbono corrente final</p></fn><fn id="t03TFN05"><label>a</label><p>A paciente realizou ambos os estudos em dec&#xFA;bito, a aproximadamente
45&#xB0;.</p></fn></table-wrap-foot></table-wrap>
</p>
        <p>Um tubo de gastrostomia foi inserido sob orienta&#xE7;&#xE3;o radiol&#xF3;gica, e a paciente passou
a ser tratada em regime de interna&#xE7;&#xE3;o domiciliar, sem planos de voltar &#xE0; cl&#xED;nica.
Sete semanas ap&#xF3;s o in&#xED;cio da VNIPP, a paciente foi contatada para ajuste da
configura&#xE7;&#xE3;o com base nos sintomas e nos dados baixados (<xref ref-type="table" rid="t04">Tabela 2</xref> e <xref ref-type="fig" rid="f02">Figura 1</xref>).
Decidiu fazer uma r&#xE1;pida visita &#xE0; cl&#xED;nica para discutir a piora da dispneia.
Apresentava dispneia leve em repouso e necessitava de uma cadeira de rodas para se
mover. A VNIPP noturna, usada todas as noites, facilitava a respira&#xE7;&#xE3;o,
permitindo-lhe dormir melhor e por mais tempo. Recentemente houvera um vazamento na
m&#xE1;scara, em virtude da perda de peso da paciente. Na &#xE9;poca, a paciente apresentava
CVF de 1,01 L (36% do previsto), PIm&#xE1;x de &#x2212;15 cmH<sub>2</sub>O (21% do previsto) e
PaCO<sub>2</sub> de 55 mmHg. A configura&#xE7;&#xE3;o do ventilador foi ajustada assim: VC =
370 mL (7 mL/kg); press&#xE3;o inspirat&#xF3;ria positiva nas vias a&#xE9;reas = 10-17
cmH<sub>2</sub>O e tempo inspirat&#xF3;rio = 1,2 s, com frequ&#xEA;ncia de
<italic>backup</italic> de 18 ciclos/min. Recomendamos o uso de VNIPP intermitente
durante o dia e um ajuste no tamanho da m&#xE1;scara. O contato com a paciente (por
telefone e e-mail) foi mantido, e as mudan&#xE7;as foram bem toleradas. Seis semanas ap&#xF3;s
sua &#xFA;ltima visita, a paciente foi novamente contatada para ajuste da configura&#xE7;&#xE3;o do
ventilador, mas n&#xE3;o quis fazer mais altera&#xE7;&#xF5;es. Pouco tempo depois, morreu de
insufici&#xEA;ncia respirat&#xF3;ria progressiva. </p>
        <p>
<table-wrap id="t04" orientation="portrait" position="float"><label>Tabela 2</label><caption><title>Dados do ventilador, baixados semanalmente, em paciente com esclerose
lateral amiotr&#xF3;fica tratada com ventila&#xE7;&#xE3;o com dois n&#xED;veis de press&#xE3;o
positiva nas vias a&#xE9;reas.</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 50%"><thead><tr><th rowspan="2" colspan="1">Vari&#xE1;vel</th><th colspan="15" rowspan="1">Semana</th></tr><tr><th rowspan="1" colspan="1">1</th><th rowspan="1" colspan="1">2</th><th rowspan="1" colspan="1">3</th><th rowspan="1" colspan="1">4</th><th rowspan="1" colspan="1">5</th><th rowspan="1" colspan="1">6</th><th rowspan="1" colspan="1">7</th><th rowspan="1" colspan="1">8</th><th rowspan="1" colspan="1">9</th><th rowspan="1" colspan="1">10<sup>a</sup>
</th><th rowspan="1" colspan="1">11</th><th rowspan="1" colspan="1">12</th><th rowspan="1" colspan="1">13</th><th rowspan="1" colspan="1">14</th><th rowspan="1" colspan="1">15</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> V<sub>E</sub>, L/min</td><td rowspan="1" colspan="1"> 4,3</td><td rowspan="1" colspan="1"> 4,5</td><td rowspan="1" colspan="1"> 4,4</td><td rowspan="1" colspan="1"> 4,4</td><td rowspan="1" colspan="1"> 4,3</td><td rowspan="1" colspan="1"> 4,5</td><td rowspan="1" colspan="1"> 5,8</td><td rowspan="1" colspan="1"> 5,4</td><td rowspan="1" colspan="1"> 5,5</td><td rowspan="1" colspan="1"> 6,5</td><td rowspan="1" colspan="1"> 7,1</td><td rowspan="1" colspan="1"> 6,4</td><td rowspan="1" colspan="1"> 5,9</td><td rowspan="1" colspan="1"> 6,3</td><td rowspan="1" colspan="1"> 6,5</td></tr><tr><td rowspan="1" colspan="1"> VC, mL</td><td rowspan="1" colspan="1"> 271</td><td rowspan="1" colspan="1"> 267</td><td rowspan="1" colspan="1"> 266</td><td rowspan="1" colspan="1"> 259</td><td rowspan="1" colspan="1"> 265</td><td rowspan="1" colspan="1"> 259</td><td rowspan="1" colspan="1"> 295</td><td rowspan="1" colspan="1"> 273</td><td rowspan="1" colspan="1"> 252</td><td rowspan="1" colspan="1"> 310</td><td rowspan="1" colspan="1"> 354</td><td rowspan="1" colspan="1"> 346</td><td rowspan="1" colspan="1"> 336</td><td rowspan="1" colspan="1"> 336</td><td rowspan="1" colspan="1"> 338</td></tr><tr><td rowspan="1" colspan="1"> Ciclos espont&#xE2;neos, %</td><td rowspan="1" colspan="1"> 77</td><td rowspan="1" colspan="1"> 82</td><td rowspan="1" colspan="1"> 77</td><td rowspan="1" colspan="1"> 78</td><td rowspan="1" colspan="1"> 76</td><td rowspan="1" colspan="1"> 80</td><td rowspan="1" colspan="1"> 90</td><td rowspan="1" colspan="1"> 87</td><td rowspan="1" colspan="1"> 78</td><td rowspan="1" colspan="1"> 63</td><td rowspan="1" colspan="1"> 55</td><td rowspan="1" colspan="1"> 47</td><td rowspan="1" colspan="1"> 43</td><td rowspan="1" colspan="1"> 46</td><td rowspan="1" colspan="1"> 50</td></tr><tr><td rowspan="1" colspan="1"> Uso di&#xE1;rio, h</td><td rowspan="1" colspan="1"> 5,0</td><td rowspan="1" colspan="1"> 3,9</td><td rowspan="1" colspan="1"> 6,1</td><td rowspan="1" colspan="1"> 5,7</td><td rowspan="1" colspan="1"> 5,4</td><td rowspan="1" colspan="1"> 5,3</td><td rowspan="1" colspan="1"> 5,6</td><td rowspan="1" colspan="1"> 6,0</td><td rowspan="1" colspan="1"> 10,1</td><td rowspan="1" colspan="1"> 12,9</td><td rowspan="1" colspan="1"> 11,8</td><td rowspan="1" colspan="1"> 12,4</td><td rowspan="1" colspan="1"> 10,3</td><td rowspan="1" colspan="1"> 13,7</td><td rowspan="1" colspan="1"> 17,6</td></tr><tr><td rowspan="1" colspan="1"> Uso &#x2265; 4 h/dia, %</td><td rowspan="1" colspan="1"> 71</td><td rowspan="1" colspan="1"> 43</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 86</td><td rowspan="1" colspan="1"> 86</td><td rowspan="1" colspan="1"> 86</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 86</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 43</td><td rowspan="1" colspan="1"> 100</td><td rowspan="1" colspan="1"> 100</td></tr><tr><td rowspan="1" colspan="1"> FR, ciclos/min</td><td rowspan="1" colspan="1"> 19</td><td rowspan="1" colspan="1"> 19</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 19</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 22</td><td rowspan="1" colspan="1"> 23</td><td rowspan="1" colspan="1"> 25</td><td rowspan="1" colspan="1"> 24</td><td rowspan="1" colspan="1"> 22</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 20</td><td rowspan="1" colspan="1"> 21</td><td rowspan="1" colspan="1"> 22</td></tr><tr><td rowspan="1" colspan="1"> IAH, eventos/h</td><td rowspan="1" colspan="1"> 15,2</td><td rowspan="1" colspan="1"> 19,4</td><td rowspan="1" colspan="1"> 25,8</td><td rowspan="1" colspan="1"> 21,6</td><td rowspan="1" colspan="1"> 19,1</td><td rowspan="1" colspan="1"> 23,2</td><td rowspan="1" colspan="1"> 5,2</td><td rowspan="1" colspan="1"> 13,4</td><td rowspan="1" colspan="1"> 22,3</td><td rowspan="1" colspan="1"> 26,8</td><td rowspan="1" colspan="1"> 7,7</td><td rowspan="1" colspan="1"> 15,1</td><td rowspan="1" colspan="1"> 11,4</td><td rowspan="1" colspan="1"> 5,5</td><td rowspan="1" colspan="1"> 12,7</td></tr><tr><td rowspan="1" colspan="1"> Vazamento, L/min</td><td rowspan="1" colspan="1"> 40</td><td rowspan="1" colspan="1"> 40</td><td rowspan="1" colspan="1"> 41</td><td rowspan="1" colspan="1"> 38</td><td rowspan="1" colspan="1"> 42</td><td rowspan="1" colspan="1"> 38</td><td rowspan="1" colspan="1"> 36</td><td rowspan="1" colspan="1"> 39</td><td rowspan="1" colspan="1"> 41</td><td rowspan="1" colspan="1"> 38</td><td rowspan="1" colspan="1"> 38</td><td rowspan="1" colspan="1"> 36</td><td rowspan="1" colspan="1"> 36</td><td rowspan="1" colspan="1"> 35</td><td rowspan="1" colspan="1"> 36</td></tr><tr><td rowspan="1" colspan="1"> PPIVA, cmH<sub>2</sub>O</td><td rowspan="1" colspan="1"> 11,9</td><td rowspan="1" colspan="1"> 11,9</td><td rowspan="1" colspan="1"> 12,9</td><td rowspan="1" colspan="1"> 12,8</td><td rowspan="1" colspan="1"> 12,5</td><td rowspan="1" colspan="1"> 12,6</td><td rowspan="1" colspan="1"> 10,9</td><td rowspan="1" colspan="1"> 11,8</td><td rowspan="1" colspan="1"> 13,5</td><td rowspan="1" colspan="1"> 15,0</td><td rowspan="1" colspan="1"> 13,8</td><td rowspan="1" colspan="1"> 13,5</td><td rowspan="1" colspan="1"> 14,2</td><td rowspan="1" colspan="1"> 14,0</td><td rowspan="1" colspan="1"> 14,5</td></tr></tbody></table><table-wrap-foot><fn id="t04TFN01"><label>VE</label><p>: ventila&#xE7;&#xE3;o minuto</p></fn><fn id="t04TFN02"><label>VC</label><p>: volume corrente</p></fn><fn id="t04TFN03"><p><bold>Ciclos espont&#xE2;neos:</bold> : ciclos respirat&#xF3;rios desencadeados pela paciente</p></fn><fn id="t04TFN04"><label>Uso di&#xE1;rio</label><p>: uso do dispositivo por per&#xED;odo de 24 h</p></fn><fn id="t04TFN05"><label>Uso</label><p> = 4 h/dia: dias em que o dispositivo foi usado durante = 4 h/ dia</p></fn><fn id="t04TFN06"><label>IAH</label><p>: &#xED;ndice de apneia-hipopneia</p></fn><fn id="t04TFN07"><p><bold>Vazamento:</bold> : vazamento total na m&#xE1;scara</p></fn><fn id="t04TFN08"><p><bold>PPIVA:</bold> : press&#xE3;o positiva inspirat&#xF3;ria nas vias a&#xE9;reas</p></fn><fn id="t04TFN09"><label>a</label><p>O suporte ventilat&#xF3;rio aumentou entre a 8&#xAA; e a 9&#xAA; semana; a 10&#xAA; semana
reflete esse aumento pela primeira semana completa.</p></fn></table-wrap-foot></table-wrap>
</p>
        <p>
<fig id="f02" orientation="portrait" position="float"><label>Figura 1</label><caption><title>Dados do ventilador durante um per&#xED;odo de 15 semanas em uma paciente com
esclerose lateral amiotr&#xF3;fica tratada com ventila&#xE7;&#xE3;o com dois n&#xED;veis de
press&#xE3;o positiva nas vias a&#xE9;reas. Nota-se o aumento da dura&#xE7;&#xE3;o do uso di&#xE1;rio
de ventila&#xE7;&#xE3;o com a diminui&#xE7;&#xE3;o da capacidade de desencadear ciclos
respirat&#xF3;rios espontaneamente (isto &#xE9;, o aumento da depend&#xEA;ncia dos ciclos
cronometrados gerados pelo ventilador) ao longo do tempo. Como se pode
observar, a ventila&#xE7;&#xE3;o minuto manteve-se relativamente constante. *O suporte
ventilat&#xF3;rio aumentou entre a 8&#xAA; e a 9&#xAA; semana; a 10&#xAA; semana reflete esse
aumento pela primeira semana completa.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-04-00443-gf01-pt"/></fig>
</p>
      </sec>
      <sec>
        <title>Discuss&#xE3;o</title>
        <p>Apresentamos o caso de uma paciente com ELA tratada com ventila&#xE7;&#xE3;o BPAP com volume
controlado no modo E-C durante 15 semanas em virtude de insufici&#xEA;ncia respirat&#xF3;ria
cr&#xF4;nica. Nessa paciente, o monitoramento semanal dos dados do ventilador mais os
cuidados de rotina forneceram informa&#xE7;&#xF5;es &#xFA;teis para o tratamento da insufici&#xEA;ncia
respirat&#xF3;ria. A progress&#xE3;o da doen&#xE7;a associou-se a piora da fraqueza muscular
respirat&#xF3;ria, diminui&#xE7;&#xE3;o da respira&#xE7;&#xE3;o espont&#xE2;nea e aumento do uso de VNIPP, embora o
VC e a ventila&#xE7;&#xE3;o minuto (V<sub>E</sub>) tenham permanecido relativamente constantes.
At&#xE9; onde sabemos, n&#xE3;o h&#xE1; relatos de casos de ELA nos quais se tenha usado esse modo
de VNIPP. </p>
        <p>Em pacientes com ELA, a progress&#xE3;o da doen&#xE7;a &#xE9; relativamente r&#xE1;pida, mas
varia.<sup>(</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> Portanto, ajustes seriais da press&#xE3;o da VNIPP podem ser necess&#xE1;rios para
compensar a diminui&#xE7;&#xE3;o da for&#xE7;a muscular respirat&#xF3;ria e o aumento da hipercapnia.
<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>)</sup> Um modo de VNIPP com varia&#xE7;&#xE3;o de press&#xE3;o inspirat&#xF3;ria (para manter um VC
alvo) em vez de press&#xE3;o fixa pode reduzir a frequ&#xEA;ncia de ajustes necess&#xE1;rios ao
longo do tempo em alguns pacientes. Esse recurso tamb&#xE9;m pode ser ben&#xE9;fico em curto
prazo, como durante o sono, quando os pacientes com fraqueza diafragm&#xE1;tica est&#xE3;o
vulner&#xE1;veis &#xE0; piora da hipoventila&#xE7;&#xE3;o, especialmente durante o sono <italic>rapid eye
movement</italic>. Ambogrio et al. mostraram que, em compara&#xE7;&#xE3;o com o modo
tradicional de ventila&#xE7;&#xE3;o BPAP E-C, o modo de ventila&#xE7;&#xE3;o BPAP E-C com volume
controlado foi mais capaz de manter a V<sub>E</sub> (por meio da manuten&#xE7;&#xE3;o do VC)
durante o sono em pacientes com s&#xED;ndrome de hipoventila&#xE7;&#xE3;o por obesidade.<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup>
</p>
        <p>O software embutido nos dispositivos de VNIPP &#xE9; privado, e, na aus&#xEA;ncia de valida&#xE7;&#xE3;o
independente, os dados relativos a muitos par&#xE2;metros devem ser considerados
indicadores de tend&#xEA;ncias, sem qualquer garantia de linearidade das
estimativas.<sup>(</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>)</sup> Apesar dessa limita&#xE7;&#xE3;o, os dados dispon&#xED;veis podem fornecer informa&#xE7;&#xF5;es
valiosas para o tratamento do paciente. Estudos envolvendo o monitoramento remoto de
dados de ades&#xE3;o &#xE0; VNIPP em pacientes com ELA usando ventila&#xE7;&#xE3;o BPAP tradicional
mostraram que, em compara&#xE7;&#xE3;o com os cuidados de rotina, esse monitoramento reduz a
utiliza&#xE7;&#xE3;o de servi&#xE7;os de sa&#xFA;de e as interna&#xE7;&#xF5;es hospitalares, potencialmente
reduzindo os custos globais de cuidados de sa&#xFA;de. <sup>(</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup> Essa modalidade de monitoramento pode ser particularmente &#xFA;til em
pacientes com ELA avan&#xE7;ada ou de progress&#xE3;o r&#xE1;pida, que, como nossa paciente, podem
ficar impedidos de sair de casa. A capacidade de solicitar altera&#xE7;&#xF5;es na configura&#xE7;&#xE3;o
e verific&#xE1;-las remotamente (sem uma visita domiciliar) &#xE9; uma vantagem adicional. </p>
        <p>A ventila&#xE7;&#xE3;o BPAP com volume controlado no modo E-C &#xE9; uma alternativa relativamente
nova &#xE0; VNIPP tradicional para pacientes com insufici&#xEA;ncia respirat&#xF3;ria, e fomos os
primeiros a relatar seu uso em um paciente com ELA. S&#xE3;o necess&#xE1;rios mais estudos a
fim de comparar os v&#xE1;rios modos de VNIPP quanto a seu efeito sobre a sobrevida,
qualidade de vida, qualidade do sono, ades&#xE3;o, adequa&#xE7;&#xE3;o da ventila&#xE7;&#xE3;o e utiliza&#xE7;&#xE3;o de
servi&#xE7;os de sa&#xFA;de em pacientes com ELA. </p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="supported-by">
          <p>Apoio financeiro: Nenhum. </p>
        </fn>
        <fn id="fn03" fn-type="supported-by">
          <label>*</label>
          <p> Trabalho realizado na Se&#xE7;&#xE3;o de Pneumologia e Medicina Intensiva, Faculdade de
Medicina da Universidade de Maryland, Baltimore (MD) EUA.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
</pmc-articleset>
